|[September 18, 2013]
Ferrer and Medivir Enter Agreement for Commercializing a New Treatment for Agitation Associated with Schizophrenia and Bipolar Disease in the Nordics
HUDDINGE, Sweden --(Business Wire)--
Medivir AB (Nasdaq OMX: MVIR) (STO:MVIR-B) and Ferrer today announced
that they have entered a license and distribution agreement for the
commercialization of ADASUVE® (Staccato® Loxapine) in the Nordic region.
In Europe, ADASUVE is approved for the treatment of mild to moderate
agitation of patients with schizophrenia or bipolar disease.
Under the terms of the agreement, Ferrer grants to Medivir the exclusive
rights to promote, market, sell and distribute ADASUVE in the Nordic
region - including Denmark, Finland, Norway, Iceland and Sweden. ADASUVE
is a hand-held inhaler designed to deliver the drug to the deep lung,
providing rapid systemic delivery in a simple, non-invasive manner.
Medivir thus becomes the exclusive supplier of this new treatment
therapy for the treatment of mild to moderate agitation of patients with
schizophrenia or bipolar disease. In return, Ferrer will receive an
up-front payment upon signature, and milestone payments conditional upon
cumulative sales performance.
"This licensing agreement is in line with our strategy to add new
products to our Nordic portfolio. ADASUVE is the first addition to the
portfolio, which now consists of 16 prescription pharmaceuticals" said
Mr Maris Hartmanis, Medivir's CEO. He added, "ADASUVE is a very
interesting product based on a novel administration technology
addressing an unmet medical need, which expands our present offering to
psychiatrists, Lithionit. We are excited about having secured the
commercial rights to ADASUVE for the Nordic region and the partnership
"We belive that ADASUVE will be a breakthrough in the treatment of
agitation and is going to change the way in which the condition is
viewed by both healthcare professionals and patients", said Mr. Antoni
Villaró, Chief Operating Officer of Ferrer. He added, "We are excited to
be introducing ADASUVE to the European psychiatric and hospital
treatment community as ADASUVE is now available in Germany, and thank to
this agreement soon in the Nordic countries."
"We take pride in developing a strong network of partners that, along
with our commercial resources, contribute to bring to the market
innovative products aimed at underserved conditions", said Mr. Pedro de
Antonio, Ferrer's International Director for Europe, Asa, Middle East
Agitation is a severe, disruptive, and morbid complication suffered by
patients with schizophrenia and bipolar disorders.
Patients who experience agitation describe feeling an inner distress
that progresses to an outwardly apparent dysfunctional state manifested
by verbal abuse, hostility, difficulty controlling impulses,
uncooperative behavior and increased potential for violence. While the
time after which agitation requires treatment can be variable (minutes,
hours or days), once the patient escalates to this point, urgent
treatment is always required.
Currently, the standard of care in the treatment of acute agitation is
pharmacological tranquilization with antipsychotics, sometimes combined
ADASUVE, an inhaled formulation of the antipsychotic drug loxapine,
begins to control patients' agitation in less than 10 minutes,
intercepting the onset of agitation in a noninvasive manner.
About ADASUVE (Staccato Loxapine)
ADASUVE combines the proprietary Staccato system with loxapine, an
antipsychotic medicinal product. The Staccato system is a hand-held
inhaler that delivers a drug aerosol to the deep lung resulting in
intravenous-like pharmacokinetics and rapid systemic effects.
ADASUVE has been approved for marketing in the EU by the European
For more information about ADASUVE, including the Summary of Product
Characteristics and Patient Information Leaflet approved in the EU
please visit: http://www.adasuve.com/index-eu.php
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a
strong infectious disease R&D portfolio. The Company's key pipeline
asset is simeprevir, a novel protease inhibitor in late phase III
clinical development for hepatitis C that is being developed in
collaboration with Janssen R&D Ireland.
Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.
For more information, visit www.medivir.com
Ferrer is a privately-held European R&D-based pharmaceutical company
headquartered in Barcelona. It is active in the pharmaceutical, health,
fine chemicals and food sectors in Europe, Latin America, Africa, the
Middle East, Asia and the United States. In total, Ferrer's human
healthcare products are commercialized in more than 90 countries,
through 23 international affiliates (including joint ventures) and 70
partners and distributors.
Ferrer carries out activities throughout the full pharmaceutical value
chain, from R&D to international marketing, including fine chemical
development and the manufacturing of both raw materials and finished
pharmaceuticals. Its research centers in Spain and Germany, and
manufacturing sites in Europe and Latin America cover the
pharmaceutical, diagnostics, vaccine, fine chemical, food and feed
Ferrer holds the commercial rights for ADASUVE in Europe, Latin America,
Russia and the Commonwealth of Independent States countries. ADASUVE®
and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
For more information, visit www.ferrergrupo.com
This information was brought to you by Cision http://news.cision.com
[ Back To Technology News's Homepage ]